luminal B breast carcinoma

Summary

luminal B breast carcinoma (MONDO:0021115) is a cancer with 7 GWAS associations across 7 studies and 9 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous and oleclumab. A subtype of breast tumor luminal A or B — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• GWAS associations: 7
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	luminal B breast carcinoma
Mondo ID	MONDO:0021115
DOID	DOID:0080674
NCIT	C53555
UMLS	C3642346
MedGen	770986
Is cancer (heuristic)	yes

Also known as: Luminal B · Luminal B breast cancer · Luminal B breast carcinoma · Luminal B estrogen receptor positive subtype of breast carcinoma · Luminal B oestrogen receptor positive subtype of breast carcinoma · Luminal B subtype of breast carcinoma

Data availability: 7 GWAS associations (7 studies).

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › breast carcinoma by gene expression profile › breast tumor luminal A or B › luminal B breast carcinoma

Related subtypes (1): luminal A breast carcinoma

Genetics & variants

GWAS landscape

7 GWAS associations across 7 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs13258434	2e-09	NACA4P - LINC02845	G	0.03
rs1243184	2e-08	MLLT10	T	0.03
rs10873406	1e-07	GPR68 - CCDC88C	G	0.02
rs10890844	2e-07	C11orf65	C	0.02
rs7589172	3e-07	RPS2P18 - CDCA7	A	0.02
rs4752568	3e-07	FGFR2	C	0.02
rs12403443	4e-07	KIF1B	A	0.02

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90446471	Sun X	2024	16,499	0	Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
GCST90446472	Sun X	2024	16,499	0	Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
GCST90454346	Zhang H	2020	13,800	91,477	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
GCST90454347	Zhang H	2020	13,800	91,477	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
GCST90446468	Sun X	2024	12,414	0	Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
GCST90446473	Sun X	2024	5,859	0	Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants that Confer Risk for Breast Cancer.
GCST90319679	Hsu YC	2023	234	0	The largest genome-wide association study for breast cancer in Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	5
intergenic_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs13258434	8	101379857	G>A,T	0.05	intergenic_variant	NACA4P - LINC02845	2e-09	Tier 4: intronic/intergenic
rs1243184	10	21643008	T>C	0.05	intron_variant	MLLT10	2e-08	Tier 4: intronic/intergenic
rs10873406	14	91255717	G>A,T	0.05	intergenic_variant	GPR68 - CCDC88C	1e-07	Tier 4: intronic/intergenic
rs10890844	11	108463400	T>C	0.05	intron_variant	C11orf65	2e-07	Tier 4: intronic/intergenic
rs7589172	2	173342742	A>C	0.05	intron_variant	RPS2P18 - CDCA7	3e-07	Tier 4: intronic/intergenic
rs4752568	10	121571027	C>G,T	0.05	intron_variant	FGFR2	3e-07	Tier 4: intronic/intergenic
rs12403443	1	10363930	A>G	0.05	intron_variant	KIF1B	4e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06585969	PHASE3	WITHDRAWN	A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
NCT03875573	PHASE2	ACTIVE_NOT_RECRUITING	Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
NCT03356860	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
NCT05163106	PHASE2	COMPLETED	Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
NCT05640778	PHASE2	UNKNOWN	Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
NCT06805084	Not specified	ACTIVE_NOT_RECRUITING	Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas
NCT03715959	Not specified	COMPLETED	Nipple Aspirate Fluid in Detecting Breast Cancer
NCT03860740	Not specified	COMPLETED	Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients
NCT04118062	Not specified	COMPLETED	Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	1
OLECLUMAB	3	1